Patent intelligence · US
US 8388969
Interleukin-1 alpha antibodies and methods of use
Interleukin-1 alpha antibodies and methods of use
Patent details — US 8388969
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 5, 2013
- Expiration
- Feb 28, 2033
- Applicant
- XBIOTECH INC.
- Claims
- 1
- CPC classes
- A61K, A61K2039/55527, A61K39/3955, A61P
Quick answer
US 8388969 (Interleukin-1 alpha antibodies and methods of use) is held by XBIOTECH INC.. Status: granted. Granted Mar 5, 2013. Expires Feb 28, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- XBIOTECH INC.
- Grant date
- Expiration
- Claims
- 1
- CPC classes
- A61K, A61K2039/55527, A61K39/3955, A61P, A61P29/00, A61P35/00
More from XBIOTECH INC.
Related pharmaceutical patents in our USPTO index.
-
US 12116405
Arthritis treatment
granted -
US 11932688
Treatment for neoplastic diseases
granted -
US 11773157
Compositions and methods for treating and preventing Staphylococcus aureus infections
granted -
US 11529298
Cosmetic composition and its use, dermocosmetic formulation
granted -
US 11523981
Cosmetic composition and its use, dermocosmetic formulation
granted -
US 11370831
Compositions and methods for treating and preventing Staphylococcus aureus infections
granted -
US 10577410
Compositions and methods for treating and preventing Staphylococcus aureus infections
granted -
US 10294296
Treatment for neoplastic diseases
granted
Frequently asked questions
What is US patent 8388969?
US 8388969 (Interleukin-1 alpha antibodies and methods of use) is held by XBIOTECH INC.. Status: granted. Granted Mar 5, 2013. Expires Feb 28, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8388969?
XBIOTECH INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 31 pharmaceutical patents for this assignee.
When does US 8388969 expire?
Our index shows an expiration date of Feb 28, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.